Compare ADMA Biologics Inc (ADMA) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Icl Group Ltd — how do they compare? ADMA Biologics Inc trades at $9.94 (market cap $2.22B), while Icl Group Ltd trades at $5.45 (market cap $6.94B). The key difference: Icl Group Ltd is far larger — about 3.1× ADMA Biologics Inc's market cap, and Icl Group Ltd pays a 3.86% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ICL | |
|---|---|---|
Market Cap | $2.22B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $6.84 |
52-Week Low | $7.60 | $4.80 |
Enterprise Value | $2.29B | $9.58B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
ICL trades at $5.34, up 0.56% today, with a bullish technical signal supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $0.12 versus $0.11 expected, continuing a trend of positive surprises. The company maintains stable cash flow from operations around $1.1B annually and pays consistent dividends, with recent payments of $0.05 and $0.06 per share.
Outlook remains cautious with 100% analyst hold ratings citing fair valuation. Risks include declining profit margins (3.95% net margin in 2025) and exposure to commodity price volatility. The stock offers moderate value with P/E of 22.25 and P/S of 0.89, but requires monitoring of cost transformation program effectiveness amid raw material inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
